Seres Health targets microbiome, gets $48M to push fecal transplant pill into Phase 3http://medcitynews.com/2014/12/seres-he ... phase-iii/
Cambridge-based Seres Health, a contender in the haute field of microbiome therapeutics, just hauled in a $48 million Series C round. The startup’s developing biologics that target recurrent C. difficile infections – a real nuisance in the realm of hospital-acquired infections.
The company plans to use the funding to advance its lead candidate, SER-109, into Phase 3 clinical trials. If approved, Seres’ therapeutic line – called Ecobiotic – will be the first oral microbiome-related therapeutic that receives the regulatory go-ahead.
The Ecobiotic system works by “augmenting the biology of the microbiome,” Seres said. In September it released results from its earlier SER-109 trial, in which 29 of the study’s 30 patients were completely cured of their C. dificile infections over the course of 8 weeks. The patients received oral doses of Seres’ microbiome “spores” – that is, precursors to “good” gut bacteria that mature into disease-fighting agents. They’ve been isolated from human fecal matter, then delivered in pill-form to the patient – a promising approach given the growing bacterial resistance to antibiotics.